Abstract:Background Subtyping schizophrenia can disentangle heterogeneity and help with treatment decision- making. However, current schizophrenia subtypes have not demonstrated adequate clinical utility, limited by sample size, suboptimal clustering methods, and choice of clustering input. Polygenic scores (PGS) reflect the genetic risk of phenotypes including comorbidities and are available before treatment, making them candidate clustering input. Methods We derived PGS for schizophrenia, autism spectrum disorder, bipolar disorder type-1, depression, and intelligence in 4,915 schizophrenia cases with register linkage. We randomly divided the sample into discovery and replication partitions and applied a novel clustering workflow on both: preprocessing PGS, feature extraction with uniform manifold approximation and projection (UMAP), and clustering with density-based spatial clustering of applications with noise (DBSCAN). After replication, we re-performed clustering on the entire sample and evaluated treatment-relevant variables of medication and hospitalization (extracted from registers) across clusters. Outcomes We identified five well-replicated PGS clusters. Cluster 1 (26% of entire sample) with generally lower PGS, had the least use of antipsychotics (including clozapine), and fewer outpatient visits. Cluster 2 (48%) with generally higher PGS, especially schizophrenia PGS, had more prescriptions of antipsychotics including clozapine and longer treatment with clozapine. Each featured by specific PGS, clusters 3 (high IQ-PGS, 11%), 4 (high ASD-PGS, 8%), 5 (high BIP-PGS, 7%) showed sub-threshold level significance in the corresponding phenotypic measures but did not differ significantly in the treatment-relevant variables. Solely categorizing the patients with SCZ-PGS did not generate any significant patterns in the phenotypic and treatment-relevant variables. Interpretation The results suggest that combinations of PGS of brain disorders and traits can provide clinically relevant clusters, offering a direction for future research on schizophrenia subtyping. Future replications in independent samples are required. The workflow can be generalized to other disorders and with mechanism-informed PGS. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement PFS was supported by the Swedish Research Council (Vetenskapsradet, award D0886501), the Horizon 2020 Program of the European Union (COSYN, RIA Grant Agreement No. 610307), and US NIMH (U01 MH109528 and R01 MH077139). LY was supported by the US NIMH R01 MH123724 and MH124873, and the European Research Council (grant agreement ID: 101042183). KK was supported by the NIMH (MH123724) and the University of Manitoba. SY was supported by Karolinska Institutet. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The research procedures were approved by ethical committees at the Karolinska Institutet with written informed consent provided by the subjects. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All data produced in the present work are contained in the manuscript and supplementary material

Incorporating clinical, genomic profiles and polygenic risk scores for the subtyping of depressive disorders

Redefining and subtyping of major depression based on brain functional connectivity signatures with high generalization: an ensemble hybrid framework

Subphenotyping Depression Using Machine Learning and Electronic Health Records

Identifying Subgroups of Major Depressive Disorder Using Brain Structural Covariance Networks and Mapping of Associated Clinical and Cognitive Variables

Biological Subtyping of Psychiatric Syndromes As a Pathway for Advances in Drug Discovery and Personalized Medicine

Subtyping Schizophrenia Using Psychiatric Polygenic Scores

Identifying data-driven subtypes of major depressive disorder with electronic health records

Data-driven Clustering Differentiates Subtypes of Major Depressive Disorder with Distinct Brain Connectivity and Symptom Features

Intelligence As Proxy Phenotype Providing Insight into the Heterogeneity of Schizophrenia

NetMoST: A network-based machine learning approach for subtyping schizophrenia using polygenic SNP allele biomarkers

Biotypes of major depressive disorder: Neuroimaging evidence from resting-state default mode network patterns.

Distinguishing different psychiatric disorders using DDx-PRS

A Neuroimaging-based Precision Medicine Framework for Depression

Dissecting Biological Heterogeneity in Major Depressive Disorder Based on Neuroimaging Subtypes with Multi-Omics Data

Association between polygenic risk scores combined with clinical characteristics and antidepressant efficacy

Predicting Treatment Selections for Individuals with Major Depressive Disorder According to Functional Connectivity Subgroups

Genetic heterogeneity and subtypes of major depression

Biotypes of Major Depressive Disorder Identified by a Multiview Clustering Framework

Data-driven biological subtypes of depression: systematic review of biological approaches to depression subtyping

Prediction of antidepressant treatment response with thalamo-somatomotor functional connectivity revealed by generalizable stratification of depressed patients

Identification of depression subtypes and relevant brain regions using a data-driven approach